Antengene to Present Clinical Results of ATG-008 (Onatasertib) at the 2022 American Society of Clinical Oncology Annual Meeting ...Middle East

Poster will report data from the Phase I/II TORCH-2 Study that evaluates ATG-008 (onataseritb) and toripalimab in patients with advanced solid tumors TORCH-2 is the world's first clinical study evaluating the combination of a dual mTORC1/2 inhibitor and an anti-PD-1 monoclonal antibody...

Hence then, the article about antengene to present clinical results of atg 008 onatasertib at the 2022 american society of clinical oncology annual meeting was published today ( Wednesday 01/06/2022 - 03:56 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Antengene to Present Clinical Results of ATG-008 (Onatasertib) at the 2022 American Society of Clinical Oncology Annual Meeting )

Also on site :

• Driver dies in fiery freeway crash on Christmas Eve near Sacramento
• Trump’s Christmas Eve calls with children asking about Santa’s whereabouts are steeped in partisan politics
• JCPenney Has a 'Stunning' White Sapphire Jewelry Set on Sale for Just $16, and It's Perfect for Every Occasion